Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.51 USD
Change Today -0.11 / -4.20%
Volume 294.0K
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Open
$2.53
Previous Close
$2.62
Day High
$2.64
Day Low
$2.50
52 Week High
07/17/15 - $3.75
52 Week Low
12/18/14 - $1.09
Market Cap
325.3M
Average Volume 10 Days
449.0K
EPS TTM
$-0.34
Shares Outstanding
129.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma. It also develops CUDC-427 that is in Phase I clinical trials for advanced solid tumor and lymphomas; programmed death ligand-1 antagonist, which is in preclinical stage for the treatment of cancers; small molecule Interleukin-1 receptor-associated kinase 4 inhibitor that is in preclinical stage for the treatment of hematological cancers; and CUDC-305 drug candidate, which is in trials in patients with systemic mastocytosis and glioblastoma multiforme for the treatment of cancers. In addition, the company offers Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma (BCC). Its Erivedge is also in Phase II clinical trials for preceding excision and/or multiple BCC, and idiopathic pulmonary fibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

35 Employees
Last Reported Date: 02/24/15
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $464.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $399.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $409.7K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $226.3K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2014.

curis inc (CRIS) Key Developments

Curis, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Curis, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $2,082,504 compared to $4,801,285 a year ago. Net loss from operations was $7,369,416 compared to $1,544,787 a year ago. Net loss was $8,128,693 or $0.06 per basic and diluted share compared to $1,895,785 or $0.02 per basic and diluted share a year ago. The decrease in Revenue was primarily due to a decrease in license fee revenues due to a $3 million milestone payment that Curis earned from Genentech/Roche upon achievement by Genentech/Roche of certain development objectives during the second quarter of 2014. Offsetting these decreases, royalty revenues recorded on Genentech/Roche's net sales of Erivedge increased to $2.0 million in the second quarter of 2015 as compared to $1.8 million during the same period in 2014. For the six months, the company reported total revenues of $3,740,836 compared to $6,085,918 a year ago. Net loss from operations was $38,390,965 compared to $6,298,130 a year ago. Net loss was $39,976,916 or $0.34 per basic and diluted share compared to $7,459,721 or $0.09 per basic and diluted share a year ago. The company has revised its 2015 financial guidance for research and development expenses for 2015. The company currently expects that these expenses will be in the range of $30 to $35 million for 2015. The company had previously estimated that these expenses would range from $37 to $42 million. As a result, the company currently expects to end 2015 with cash, cash equivalents and investments of $72 to $77 million versus its previous estimate of $65 to $70 million.

Curis, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Curis, Inc. announced that they will report Q2, 2015 results at 9:00 AM, Eastern Standard Time on Aug 06, 2015

Curis, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Curis, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $2.51 USD -0.11

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.66 USD -0.04
CTI BioPharma Corp $1.53 USD -0.05
Cytokinetics Inc $6.86 USD -0.06
MELA Sciences Inc $1.20 USD +0.02
Navidea Biopharmaceuticals Inc $1.89 USD +0.01
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.3x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit www.curis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.